<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HA23F9996562F4903B83BDE23F35171FD" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 242 IH: Medicare Prescription Drug Price Negotiation Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-01-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 242</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170104">January 4, 2017</action-date><action-desc><sponsor name-id="W000800">Mr. Welch</sponsor> (for himself, <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>, <cosponsor name-id="D000216">Ms. DeLauro</cosponsor>, <cosponsor name-id="C000984">Mr. Cummings</cosponsor>, <cosponsor name-id="E000288">Mr. Ellison</cosponsor>, <cosponsor name-id="P000607">Mr. Pocan</cosponsor>, <cosponsor name-id="C001084">Mr. Cicilline</cosponsor>, <cosponsor name-id="K000009">Ms. Kaptur</cosponsor>, <cosponsor name-id="L000563">Mr. Lipinski</cosponsor>, <cosponsor name-id="M001143">Ms. McCollum</cosponsor>, <cosponsor name-id="C001066">Ms. Castor of Florida</cosponsor>, <cosponsor name-id="G000551">Mr. Grijalva</cosponsor>, <cosponsor name-id="L000562">Mr. Lynch</cosponsor>, <cosponsor name-id="C001068">Mr. Cohen</cosponsor>, <cosponsor name-id="L000580">Ms. Michelle Lujan Grisham of New Mexico</cosponsor>, and <cosponsor name-id="C001090">Mr. Cartwright</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and
			 Human Services to negotiate covered part D drug prices on behalf of
			 Medicare beneficiaries.</official-title></form>
	<legis-body id="HF4F8AFE981C745A992524BA654DC0B04" style="OLC">
 <section id="H776A874335FF41928606FB2F9A179A6C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medicare Prescription Drug Price Negotiation Act of 2017</short-title></quote>.</text> </section><section id="H3C3EBF9FE4864C0E9E0615D31F8E3C5C"><enum>2.</enum><header>Negotiation of lower covered part D drug prices on behalf of medicare beneficiaries</header> <subsection id="H1FCF6CD45FD04457B4C99D9546E187F8"><enum>(a)</enum><header>Negotiation by secretary</header><text>Section 1860D–11 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-111">42 U.S.C. 1395w–111</external-xref>) is amended by striking subsection (i) (relating to noninterference) and inserting the following:</text>
				<quoted-block id="HFAB6B6890FFB4F7FB4F12E247F1C6E86" style="OLC">
					<subsection id="H7993D31627394CDDA7EC484B5C43F04E"><enum>(i)</enum><header>Negotiation of Lower Drug Prices</header>
 <paragraph id="H09EC58C8299940F68BE2A904BD11975D"><enum>(1)</enum><header>In general</header><text>Notwithstanding any other provision of law, the Secretary shall negotiate with pharmaceutical manufacturers the prices (including discounts, rebates, and other price concessions) that may be charged to PDP sponsors and MA organizations for covered part D drugs for part D eligible individuals who are enrolled under a prescription drug plan or under an MA–PD plan.</text>
						</paragraph><paragraph id="H9E68A9A177BF4E7D8BD7637109E08832"><enum>(2)</enum><header>No change in rules for formularies</header>
 <subparagraph id="H0EFF826C3C5B46239593FB7495FF002F"><enum>(A)</enum><header>In general</header><text>Nothing in paragraph (1) shall be construed to authorize the Secretary to establish or require a particular formulary.</text>
 </subparagraph><subparagraph id="H0885FC0A2CEC4BB084C02543EF8FFD59"><enum>(B)</enum><header>Construction</header><text>Subparagraph (A) shall not be construed as affecting the Secretary's authority to ensure appropriate and adequate access to covered part D drugs under prescription drug plans and under MA–PD plans, including compliance of such plans with formulary requirements under section 1860D–4(b)(3).</text>
 </subparagraph></paragraph><paragraph id="HF87A6EB339CC4F05B71C6D2B12783892"><enum>(3)</enum><header>Construction</header><text>Nothing in this subsection shall be construed as preventing the sponsor of a prescription drug plan, or an organization offering an MA–PD plan, from obtaining a discount or reduction of the price for a covered part D drug below the price negotiated under paragraph (1).</text>
 </paragraph><paragraph id="HE2ED9537690B4C7D8E761AFD9C6F9B1C"><enum>(4)</enum><header>Semi-annual reports to Congress</header><text>Not later than June 1, 2018, and every 6 months thereafter, the Secretary shall submit to the Committees on Ways and Means, Energy and Commerce, and Oversight and Government Reform of the House of Representatives and the Committee on Finance of the Senate a report on negotiations conducted by the Secretary to achieve lower prices for Medicare beneficiaries, and the prices and price discounts achieved by the Secretary as a result of such negotiations.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H9492A77DF85648168F1521B0331643A6"><enum>(b)</enum><header>Effective date</header><text>The amendment made by subsection (a) shall take effect on the date of the enactment of this Act and shall first apply to negotiations and prices for plan years beginning on January 1, 2018.</text>
			</subsection></section></legis-body></bill>


